IL4R and anaphylaxis: After seven subcutaneous injections of dupilumab, the patient was exposed to the culprit mushrooms and exercised at least twice a month without notable anaphylaxis, suggesting that dupilumab may improve allergic reactions in FDEIA patients by blocking the IL-4Rα signaling pathway.